Tempus partners with Whitehawk Therapeutics to advance...

2025-10-16 09:50:45 ET More on Tempus AI, Whitehawk Therapeutics Tempus Screens Overvalued, Yet Data And Services Optionality Keeps It In Play Progress Vs. Price: Evaluating Tempus AI's High Valuation Thesis Tempus AI: Temporarily Too Expensive - Sell Cathie Wood's Ark Invest weekly recap: lifts stake in Bullish and Brera, trims Roku and Tempus AI Tempus gets U.S. FDA clearance for updated Tempus Pixel Device Read the full article on Seeking Alpha For further details see: Tempus partners with Whitehawk Therapeutics to advance cancer research